Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

from Listen to The Lancet Infectious Diseases · host The Lancet

Amir Shroufi discusses the early results assessing the safety and efficacy of the combination of bedaquiline and delamanid against drug-resistant tuberculosis.

Episode metadata supplied by the publisher feed · Published Feb 14, 2018

Embed this episode

Attribution link and audio player

Ready to play

Bedaquiline and delamanid combination for drug-resistant TB: The Lancet Infectious Diseases: February 13, 2018

0:00 15:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Infectious Diseases?

This episode is 15 minutes long.

When was this Listen to The Lancet Infectious Diseases episode published?

This episode was published on February 14, 2018.

Can I download this Listen to The Lancet Infectious Diseases episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!